European Radiopharmaceuticals & Stable Isotopes Market 2013-2017 -- DUBLIN, January 9, 2014 /PRNewswire/ -- DUBLIN, January 9, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/tz54gw/european_nuclear) has announced the addition of the "European Radiopharmaceuticals & Stable Isotopes Market 2013-2017" report to their offering. The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects, radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy. Germany accounted for the largest market share of the European nuclear medicine market, followed by France in 2012. Major players in the radiopharmaceuticals market are Covidien, Plc, GE Healthcare, IBA Group, Lantheus Medical Imaging, Inc., Nordion, Inc., and Siemens Healthcare (PETNET). The stable isotopes market is dominated by deuterium (D2), oxygen-18 (O-18), carbon-13 (C-13), and nitrogen-15 (N-15). It has major applications in research, pharmaceuticals, diagnostic and therapy, and the industrial sector. The diagnostic and therapy market accounted for the maximum share of the stable isotopes market. The European stable isotopes market was valued at close to $25.0 million in 2012, and is estimated to grow at a CAGR of more than 8.0% by 2017. The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) and Sigma Aldrich - in 2012; they jointly contributed more than 50% to the European revenue. 1 Introduction 1.1 Key Take-Aways 1.2 Report Description 1.3 Markets Covered 1.4 Stakeholders 1.5 Research Methodology 3 Market Overview 3.1 Introduction 3.2 Definition Of Radiopharmaceuticals 3.3 Evolution 3.4 Market Segmentation 3.5 Market Dynamics 3.6 Winning Imperatives 3.7 Burning Issues 3.8 Regulatory Affairs 3.9 Market Share Analysis 4 European Radiopharmaceuticals Market, By Isotope 4.1 Introduction 4.2 Diagnostic Market 4.3 Therapeutic Isotopes 5 European Radiopharmaceuticals Market,By Application/Indication 5.1 Introduction 5.2 Diagnostic Application 5.3 Therapeutic Application 6 European Enriched Stable Isotopes Market 6.1 Introduction 6.2 Market Overview 6.3 Market Dynamics 6.4 Enriched Stables Market, By Isotope 6.5 Enriched Stables Market, By Application 7 Geographic Analysis 7.1 Introduction 7.2 Germany 7.3 France 7.4 U.K. 7.5 Spain 7.6 Italy 7.7 Russia 7.8 Rest Of Europe 8 Competitive Landscape 8.1 Introduction 8.2 Mergers & Acquisitions 8.3 Agreements, Partnerships, Collaborations & Joint Ventures 8.4 New Products Launch 8.5 Expansions 8.6 Other Developments Bracco Imaging SPA Cambridge Isotope Laboratories, Inc Cardinal Health, Inc Covidien, Plc Eczacibasi-Monrol GE Healthcare (Subsidiary Of General Electric Company) IBA Group Isotec, Inc (Sigma-Aldrich) Lantheus Medical Imaging, Inc NTP Radioisotopes (Pty), Ltd Nordion, Inc Petnet Solutions, Inc (A Subsidiary Of Siemens Medical Solutions USA, Inc) Rotem Industries, Ltd, Inc Taiyo Nippon Sanso Corporation Urenco Limited Institutes Mentioned in the Report Australian Nuclear Association And Technology Organization (ANSTO) Institute Of Atomic Energy Polatom Radioisotope Centre Institute Of Isotopes Co, Ltd Institute Of Radioelement (IRE) For more information visit http://www.researchandmarkets.com/research/tz54gw/european_nuclear